| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Applied Therapeutics, Inc.$0.1
0 (-0.58%)
C 46Pipeline Score Fair Value Pharma · Clinical
Market Cap
14.86 M
EPS
-0.10
P/E Ratio
-
Value Trade
282.10 K
SEC Financials
Q3 2025Dilution Risk
Revenue
1.00 M
R&D Expenses
9.60 M
Total Assets
34.37 M
Total Liabilities
34.94 M
Equity
-561.00 K
D/E Ratio
12,345
3 %
Week
3 %
1 Month
-89.7 %
3 Month
-78.54 %
6 Month
-99.63 %
5 Year
-98.72 %
All Time
Cash Data
Cash Position
11.95 M
Monthly Burn
5.59 M
Runway
0 mo
Burn Trend
SEC Filing
Nov 13, 2025
Overview
Volume
2.70 M
52 Week Range
0.09 - 1.50
% held by Insiders
5.69 %
% held by Institutions
59.79 %
Enterprise Value
5.42 M
Total Shares
144.32 M
Short %
1.11 %
Float Shares
131.33 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C46
Pipeline Score $42M
Pipeline ValueFair Value
Valuation Signal9
Drugs Scored2.8x
rNPV / MCap Top 67%
Micro Cap (rank 302 of 911)
Percentile RankApplied Therapeutics, Inc. carries a moderate pipeline score (46/100), with $1.9B risk-adjusted pipeline value, led by IMM-101 in Cancer (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMM-101 Monoclonal antibody | Cancer | Phase 3 | NCT04442048 | 53% | $708M | COMPLETED | 195 | - | - | Dec 22, 2025 | - | Dec 30, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
govorestat Priority | CMT-SORD | Phase 2/3 | 2025-05-18 | 37% (p=0.005) reduction of sorbitol in the sciatic nerve; statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb domain at 12 months; statistically significant improvement in CMT-HI; statistically significant correlation between percent change in sorbitol and change in CMT-HI at 12 months Read More | Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting Read More | |
govorestat Priority | CMT-SORD | Phase 2/3 | 2025-05-18 | 37% (p=0.005) reduction of sorbitol in the sciatic nerve; statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb domain at 12 months; statistically significant improvement in CMT-HI; statistically significant correlation between percent change in sorbitol and change in CMT-HI at 12 months Read More | Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting Read More | |
govorestat Priority | CMT-SORD | Phase 2/3 | 2025-05-18 | 37% (p=0.005) reduction of sorbitol in the sciatic nerve; statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb domain at 12 months; statistically significant improvement in CMT-HI; statistically significant correlation between percent change in sorbitol and change in CMT-HI at 12 months Read More | Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in APLT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
APLT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How APLT ranks across every disease it competes inCompetitive Position is a premium feature
See how APLT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial